Cannabis-Based Dronabinol Could Transform Alzheimer's Care, New Study Finds

A recent study has found that dronabinol, a synthetic version of THC (the primary psychoactive component in cannabis), effectively reduces agitation in Alzheimer's patients.

Presented at the International Psychogeriatric Association conference in Buenos Aires, Argentina, the study reveals that dronabinol can decrease agitation symptoms by an average of 30%, offering a promising alternative to current treatments, Earth.com reported.

See Also: Could CBD Revolutionize Alzheimer’s Treatment? New Study Explores Its Neuroprotective Properties

Understanding Agitation In Alzheimer's

Alzheimer’s disease is the most prevalent neurodegenerative disorder in the United States, impacting around 6.7 million people aged 65 and older. Experts expect this number to rise to 13.8 million by 2060.

Among the challenging symptoms of Alzheimer's is agitation, which affects about 40% of patients. This can include ...

Full story available on Benzinga.com